Small cell lung cancer transformation during antitumor therapies: A systematic review

Código QR

Small cell lung cancer transformation during antitumor therapies: A systematic review

Lung cancer is the most common cause of cancer-related death. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two major histological categories of lung cancers. Drug resistance is a great challenge for cancer treatment, and histological transformation from NSCLC to SCLC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chai Xing, Zhang Xinru, Li Wenqian, Chai Jin
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	transformation nsclc sclc Medicine R
Acceso en línea:	https://doaj.org/article/7c7b5d0ce5b64da0a7fff78444a2a7a8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Severe hyponatremia due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in non-small cell lung carcinoma transforming to small cell lung carcinoma during treatment with immune checkpoint inhibitor
por: Vicky Mai, et al.
Publicado: (2021)

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
por: Kauffmann-Guerrero D, et al.
Publicado: (2020)

Synergistic alterations in the multilevel chromatin structure anchor dysregulated genes in small cell lung cancer
por: Dan Guo, et al.
Publicado: (2021)

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
por: Man He, et al.
Publicado: (2021)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
por: Youwen Zhu, et al.
Publicado: (2021)

High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells
por: Tian H, et al.
Publicado: (2016)

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Meng Yuan, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression
por: Sun Butong, et al.
Publicado: (2021)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety D
Publicado: (2019)

Identification of circRNA_001846 as putative non–small cell lung cancer biomarker
por: Fan Yang, et al.
Publicado: (2021)

Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field
por: Huzaifa Piperdi, et al.
Publicado: (2021)

Identification of lncRNA–miRNA–mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor
por: Ting Wang, et al.
Publicado: (2021)

Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
por: Lei Lei, et al.
Publicado: (2021)

Preparation and antitumor evaluation of self-assembling oleanolic acid-loaded Pluronic P105/D-α-tocopheryl polyethylene glycol succinate mixed micelles for non-small-cell lung cancer treatment
por: Wu H, et al.
Publicado: (2016)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini N, et al.
Publicado: (2021)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
por: Mehta A, et al.
Publicado: (2020)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Diego Kauffmann-Guerrero, et al.
Publicado: (2021)

Role of Rho Guanine Nucleotide Exchange Factors in Non-Small Cell Lung Cancer
por: Rui-Jie Zeng, et al.
Publicado: (2021)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
por: Yang Teng, et al.
Publicado: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg F, et al.
Publicado: (2019)

Association of expression and genotypes of thymidylate synthase in non-small cell lung cancer patients with different clinicopathological characteristics
por: Chen Jin-Yin, et al.
Publicado: (2021)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Takuma Imakita, et al.
Publicado: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Chengming Liu, et al.
Publicado: (2021)

circAGFG1 sponges miR-28-5p to promote non-small-cell lung cancer progression through modulating HIF-1α level
por: Ma Xiaoan, et al.
Publicado: (2021)

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
por: Rui Wan, et al.
Publicado: (2021)

AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1
por: Ruing Zhao, et al.
Publicado: (2021)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore VH, et al.
Publicado: (2018)

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
por: Dan Yan, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Evaluation of Predictive Values of Naples Prognostic Score in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
por: Guo D, et al.
Publicado: (2021)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami S, et al.
Publicado: (2017)

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
por: Alessio Bruni, et al.
Publicado: (2021)

Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
por: Alessio Bruni, et al.
Publicado: (2021)

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation
por: Abdallah N, et al.
Publicado: (2018)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette W, et al.
Publicado: (2017)

MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer
por: Hongli Pan, et al.
Publicado: (2021)

Iron oxide magnetic nanoparticles combined with actein suppress non-small-cell lung cancer growth in a p53-dependent manner
por: Wang MS, et al.
Publicado: (2017)

Correlation of serum electrolytes with serial miRNA in advanced stage non-small cell lung cancer (NSCLC) in Indonesia
por: Arif Riswahyudi Hanafi, et al.
Publicado: (2021)